Cyclacel Pharmaceuticals
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Cyclacel Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).
Cyclacel Pharmaceuticals: 13 sponsored US clinical trials, none currently recruiting.
Cyclacel Pharmaceuticals sponsors 13 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 8 completed. 1 of these trials are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Relapsed or Refractory Chronic Lymphocytic Leukemia, with 1 trials.
Top-decile sponsor footprint
Cyclacel Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
8 of 13 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (61.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
13 total, page 1 of 1
Absorption, Metabolism, and Excretion of CYC065 in Healthy Male Subjects
NCT05817890
CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS
NCT04017546
A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS
NCT03884829
CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL
NCT03739554
A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers
NCT02552953
A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT01303796
A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors
NCT00999401
A Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer
NCT00885963
Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients
NCT00590187
A Phase I Pharmacologic Study of CYC116, an Oral Aurora Kinase Inhibitor, in Patients With Advanced Solid Tumors
NCT00560716
A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma
NCT00476554
Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer
NCT00372073
Safety and Pharmacology Study of Sapacitabine to Treat Advanced Leukemias or Myelodysplastic Syndromes
NCT00380653
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 4 |
| Phase 3 | 1 |
Therapeutic Areas
How the Cyclacel Pharmaceuticals early-phase archive is shaped
13 indexed studies, none listed as recruiting (0% open); 8 completed (62%).
Phase mix: 1 late (III/IV) vs 12 early (I/II) (early-phase heavy).
Top condition: Relapsed or Refractory Chronic Lymphocytic Leukemia (1 trial), 2 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Cyclacel Pharmaceuticals: archived-pipeline peers nationwide
Peers matched on 13 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Cyclacel Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 13 archived trials
- Adaptimmune · 13 trials · 0% recruiting
- Agennix · 13 trials · 0% recruiting
- Akili Interactive Labs · 13 trials · 0% recruiting
- Alumis · 13 trials · 8% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Cyclacel Pharmaceuticals page
13 registered trials is a research-attention snapshot, not an endorsement of Cyclacel Pharmaceuticals or any single study.
- None of Cyclacel Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Relapsed or Refractory Chronic Lymphocytic Leukemia is the condition Cyclacel Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Relapsed or Refractory Chronic Lymphocytic Leukemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Cyclacel Pharmaceuticals pipeline card: 13 registered trials from official public datasets.Report a data error.